Patients with non-small-cell lung cancer, especially those with lung adenocarcinoma, are prone to mutations in a variety of driver genes, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and other mutations. Here, ALK is linked to lung adenocarcinoma.